Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

Table 2 Calculation of utility decrements

	Duration*	Utility	Calculation	Description
Acute Coronary Syndrome G5	30	0.68	0.87 − 0.19	[47, 48, 52]
Acute Coronary Syndrome G4	30	0.68	0.87 − 0.19 + 0.02	Assumption based on similar studies
Heart Failure G5	90	0.56	0.87 − 0.31	[49]
Heart Failure G4	90	0.56	0.87 − 0.31 + 0.02	Assumption based on similar studies
Cardiac Arrest G5	90	0.609	0.87 − 0.261	[49, 50]
Stroke G4	180	0.64	–	[49]
Gastric Hemorrhage G4	30	0.696	0.87 − 0.174	[50]
Chest Pain G3	30	0.69	–	[49]
Myocardial Infarction G3	180	0.75	–	[49]
Atrial Fibrillation G3	90	0.65	–	[49]
Rectal Hemorrhage G3	30	0.696	0.87 − 0.174	[50]
Gastrointestinal Pain	30	0.68	–	Derived from the model
Colonic Hemorrhage	30	0.696	0.87 − 0.174	[50]
Dizziness	30	0.68	–	[51]
Diarrhea	30	0.72	–	[52]
Oral Hemorrhage	30	0.696	0.87 − 0.174	[50]
Baseline	–	0.87	–	[6, 47]

*Duration is estimated in days based on the literature and on the experts' opinion; G indicates grade

ISSN: 1479-7364